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Evidence-based investment in prevention is crucial in addressing Australia’s rising health, economic and 
social burden from lifestyle-related non-
communicable diseases (NCD).1 Prevention 
strategies are prominent in the World Health 
Organization’s ‘best buys’ in addressing this 
burden.2 Despite such evidence, investment 
in prevention of NCDs in Australia is low 
compared to other countries with similar 
epidemiological profiles.3,4 Such disparity 
in expenditure potentially reflects a low 
value attached to the evidence around its 
effectiveness and cost-effectiveness by policy 
makers in this country. However, we note that 
a recent report argues that the proportional 
amount of spending on prevention by a 
country, compared to others, may be an 
overly simplistic means to assess its value or 
worth.5
In the past 20 years, the use of economic 
evidence in Australia has been growing 
through the pioneering initiatives in the 
1990s to introduce cost-effectiveness criterion 
in the listing of new drugs for government 
subsidy through the Pharmaceutical Benefits 
Advisory Committee (PBAC).6 In spite of 
the recognised leadership role Australia 
has played in institutionalising the use of 
economic evidence in informing investment 
in healthcare (such as PBAC, as well as 
the Medical Services Advisory Committee 
[MSAC]), little has been done to promote 
greater use of cost-effectiveness evidence in 
NCD prevention. 
A reason for this may be that in the 
prevention space, unlike that of healthcare, 
policy makers may be less willing to cede 
discretion over investment decisions to an 
evidence-based approach that is driven by 
cost-effectiveness. In principle, the role of 
economic evidence is to guide the allocation 
of resources efficiently across population 
groups and individuals by identifying 
programs that optimise social outcomes for 
given resources.7 However, economic analysis 
tends to be underpinned by a reductionist 
perspective on investment decision making. 
In this world view, decisions are characterised 
by a choice to either accept or reject an 
investment proposal by benchmarking 
the observed incremental cost per unit of 
health outcome of the intervention against 
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Abstract
Objective: In the context of growing financial pressures on health budgets, cost-effective 
prevention strategies are needed to address the burden from non-communicable disease in 
Australia. We explored how decision makers use economic evidence to inform such investment 
and how such evidence generated can more effectively meet the needs of end users.
Methods: Thematic analysis of in-depth interviews with 15 high level stakeholders (Treasury, 
state health departments and the insurance industry), supplemented by documentary analysis.
Results: Types of prevention approaches and economic evidence relevant to decision 
makers differed by organisational perspective. Capacity building in understanding economic 
evaluations and research evidence that addresses the differing criteria for investment used 
by different organisations is needed. The task of determining investment priorities in disease 
prevention comes with significant challenges including ideological barriers, delayed outcome 
measures, and implementation uncertainties.
Conclusions and Implications for public health: Promoting the greater use of economic 
evidence in prevention requires more work on two fronts: tailoring the methods used by 
economists to better match the organisational imperatives of end users; and promoting 
greater consideration of broader societal and health sector perspectives among end users. 
This will require significant infrastructure development, monitoring and evaluation, stronger 
national leadership and a greater emphasis on evidence coproduction. 
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an accepted cost-effectiveness threshold 
(in Australia this has been posited as being 
between $50,000–70,000 per quality adjusted 
life year gained). The logic underlying this is 
that with successive decisions made on the 
basis of this balancing of costs and outcomes, 
as a community, we are led incrementally 
toward a hypothetical efficiency ideal (or 
‘frontier’).8 One possible reason for the 
exception of prevention to this logic is that 
the outcomes of interventions are often 
multi-dimensional, long-term and diffuse – 
affecting sectors outside of health.9 As such, 
while this has a high degree of acceptance as 
a framework for allocating resources in many 
parts of the health sector, it may be at odds 
with prevailing norms that govern the way 
investments are made in prevention.10-14 
Therefore, gaining a better understanding of 
key actors’ perspectives (as depicted in Figure 
1) is vital in identifying the factors that drive 
investment decisions and in overcoming any 
perceived barriers to the implementation of 
evidence-based prevention strategies into 
practice and policy.10,15-17 For this study, we 
explored how decision makers (policy makers, 
insurers and funders) use economic evidence 
to inform investment in the prevention of 
lifestyle related NCDs, and identified how 
economic evidence can better match their 
needs. 
Methods 
Our methods are outlined here according to 
criteria for qualitative research.18,19
Approach
The study was carried out and supported by 
a research collaboration that promotes multi-
disciplinary research into chronic disease 
prevention, with a focus on developing 
system solutions. The interview guide 
(Supplementary file 1) was developed by 
health economists and covered the following 
key questions: What type of evidence is 
used when making investment decisions in 
disease prevention? What role does economic 
evidence play? What types of analyses are 
used? Is there scope for generating economic 
evidence that better matches decision 
makers’ needs? 
Setting and sampling strategy
Recruitment of the participants was 
purposive. We sought to elicit views from 
individuals within three distinct types of 
organisations: state health and Treasury 
departments and private health insurance 
companies. The research collaborators helped 
identify key individuals who were responsible 
for investment decisions. An ethics-approved 
information sheet and invitation letter were 
sent to potential participants. Ethics approval 
was granted by University of Sydney before 
commencement of research. 
Data collection techniques
We conducted semi-structured interviews 
with these decision makers that lasted 
between 30 and 45 minutes. All participants 
provided written informed consent. A health 
economist took the lead in conducting the 
face-to-face interviews, accompanied by two 
public health researchers with backgrounds 
in medicine and law, respectively. Three 
interviews were conducted on the phone due 
to distance. All interviews were recorded with 
a digital recorder. Any supporting documents 
referred to by the interviewees were obtained 
by the team so they could be analysed. 
Analysis
Interviews were professionally transcribed 
verbatim and managed by NVivo software. 
A coding framework (Supplementary file 2) 
was developed using a ‘ground up’ approach 
by the two public health researchers using 
three transcripts and iterative changes made 
as necessary with the coding of subsequent 
transcripts. The team met regularly to discuss 
the emerging themes. Thematic saturation 
was reached at 15 participants and interviews 
were stopped. Constant comparison 
across cases was undertaken as all data 
coded to each major code was analysed. 
Documents20-31 referred to by participants 
during the interviews were analysed by a 
senior health economics researcher for the 
purpose of triangulating the findings.32 The 
findings from the documentary analysis are 
provided in Supplementary file 3. 
Results
We interviewed high-level decision makers; 
four were from the insurance industry, 
eight from state health departments and 
three from a state Treasury department. 
Three key themes were derived about how 
organisational perspectives frame types 
of economic evidence used; the need to 
increase the accessibility and acceptability 
of health economics to end users; and 
the significant barriers to the prevention 
agenda. Further illustrative quotes are 
Figure 1: Contextual map of stakeholders. The complexities of the provision of prevention strategies by various 
stakeholders, highlighting their roles and interlocking relationships which impact upon the consumer’s behaviour 
change.
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presented in Box 1. Table 1 presents a 
summary of the identified barriers to the use 
of economic analysis in prevention and our 
recommendations to address them. 
Organisational perspectives frame the 
preferred prevention approaches and 
types of economic evidence used 
Industry (insurance companies) – business 
case and return on investment 
The industry perspective focused on the use 
of economic evidence to justify their business 
case and stewardship of members’ funds. 
Industry stakeholders wanted evidence 
relating to the minimisation of hospitalisation 
for their members and consequently 
defined ‘return on investment’ in those 
terms, as this was the most tangible means 
of demonstrating value to the business. In 
comparison, primary prevention or health 
promotion activities were highlighted by 
another insurer as part of their ‘branding’ and 
marketing campaign. Industry stakeholders 
also described how cost savings generated 
by their programs were often realised in the 
public sector (e.g. reduced pharmaceutical 
costs through Medicare), but indicated that 
these were generally not factored into the 
company’s decision making. One option 
raised was the possibility of cost-sharing 
arrangements with government in which 
there were mutual benefits.
Health departments – population health 
approach 
Health department stakeholders described 
using an evidence-based approach to 
demonstrate the potential benefits of a 
concerted prevention strategy with a ‘range 
of interventions’ and indicated that there was 
a need to incorporate other sectors. These 
stakeholders recognised that economic 
evidence would provide greater ‘credibility’ 
for what they do, although some described 
a reticence to use financial outcomes and a 
preference to only focus on health outcomes. 
A health policy maker indicated the advocacy 
value of cost of illness evidence such as 
“the cost of overweight and obesity being 
estimated to be 19 billion dollars a year” as a 
way of effectively framing the problem as a 
community rather than an individual issue. 
Economic evidence such as costing data 
(rather than cost- effectiveness evidence) 
was used primarily to better inform the 
implementation of programs, and less so 
to set broader priorities. Two health policy 
makers perceived that economic evidence 
Box 1: Illustrative quotes across themes.
 Organisational perspectives frame the preferred prevention approaches and types of economic evidence used 
“… we are involved in activities which I would probably classify as primary prevention, but it’s not a deliberate investment activity, it’s 
more from a brand activity … So, we like to shoot positive health messages out there to the general population in regards to good diet 
and exercise behaviours …” (Insurer perspective)
“But we don’t have those answers. You’re getting to sort of where we get frustrated. I mean return on investment, as we are able to use 
it, gives us some sense of being able to compare, say one cooking program against another cooking program. It’s useful in that sense in 
that we can get some sense of, which is the most technically efficient program if you like. And we can purchase on that basis … we can’t 
compare, one type of approach to another type of approach (for example, advertising, changing environments or in advertising versus, 
you know, a diabetes risk assessment tool) with the tools that we have available to us or any of the return on investment analysis that I’ve 
seen anywhere. And that is the holy grail process.” (Health perspective)
“We kind of take the whole of government approach ... A program might require investment through the health sectors, through the 
education sectors, family and community services and it’s about understanding holistically… You’ve got a number of service sectors, sort 
of involved in this and whilst success in one sector doesn’t necessarily mean, you know, success in say, education or family and community 
services. So, it’s about looking at the whole across government, how much is it going to cost across government, what are the benefits 
across government.” (Treasury perspective)
Increasing acceptability and accessibility of health economics to end users
“I think they (other government agencies) confuse the word economic analysis with financial analysis. There’s just no way in reality 
that the agencies are currently geared up for that kind of thing. Completely missing that capability. We want to build up capability 
and understanding of those things … So, there’s a series of opportunities there to work with government (about what) would be an 
acceptable kind of framework that we can all agree on so that we can sort of move the debate forward onto then what sort of things we 
should be funding.” (Treasury perspective)
“I think from my perspective I feel like (the use of economic evidence) is an area I hardly know anything about and so I reckon that there’s 
a role for, you know, economic evaluation 101 for senior managers … It would also be really helpful for me … in the area of overweight 
and obesity or tobacco control or alcohol ¬– preventing alcohol related harm – [to know] what’s the current landscape, what in terms of 
economic evaluation of intervention and policy in those areas, is really helpful for someone in my role.” (Health perspective)
“So, then what I’m looking at is my health economists have gone away and done some really nice modelling around the types of people 
that will be going through [a health program]. So, they’re over 60 and they look like this and therefore, on average, and depending on all 
those variables, we have different combinations, this is what they would expect to cost … I’m going to say that I’m forecasting 30 to 40% 
reduction in patients re-admitting over a 90-day time frame that go through this program, so therefore how does that stack up?” (Insurer 
perspective)
Prevention agenda for NCD faces significant challenges 
“So, in tobacco I think there’s not so much contention around tobacco as an area where government would intervene. We’ve got 30 years 
of evidence in relation to [success], so these policy changes and these programmatic and services are an appropriate mix. Whereas, in 
overweight and obesity, it’s not as well clearly understood, nor is it equally accepted as a place for government intervention.” (Treasury 
perspective)
“Because we would often get a phone call from the (funders) saying okay, you’ve now spent this huge investment in prevention. How 
many kids did you stop from becoming obese? Now that’s quite a hard question to answer. Not reducing …the number of kids who are 
(overweight) down into the healthy weight area, but how many did you stop from going up the scale into the unhealthy weight?” (Health 
perspective)
“In the health space, we know there’s a kind of cost trajectory valve, and health costs are going to rise into the future. And you know, we 
need to be doing more about keeping people out of hospital to start with … there is a recognition that we need to be investing in health. 
it’s a question of what we should be investing in … that the proposed [strategy], you know it’s worked elsewhere, is it actually going to 
work here? Do we have the right conditions, capacity and capability?” (Treasury perspective)
that tackled allocative efficiency questions 
across different types of prevention strategies 
would be the ‘holy grail’ in informing their 
decisions. 
Treasury – whole-of-government and inter-
sectoral approach
Treasury decision makers stated the use of 
a ‘whole-of-government approach’ in the 
assessment of inter-sectoral prevention 
interventions and indicated they would 
consider costs and benefits across 
government. Return on investment and the 
‘bottom line’ did come into play; however, 
they were also concerned with broader 
economic dynamics such as inter-sectoral 
(e.g. transport and education) contributions 
to investments and their roles in promoting 
healthy living and the economic impact of 
improved health status. 
Increasing acceptability and 
accessibility of health economics to 
end users
Capacity building in health economics for 
end users
Some stakeholders in health and Treasury 
indicated that the health sectors’ capacity 
to understand economic evidence was 
limited, and capacity should be built either 
through collaborations or workshops. A 
high-level policy maker in health stated, 
“there’s a role for economic evaluation 
101 for senior managers”. Interviews often 
ended with requests from the interviewees 
for documents that synthesised the cost-
Liu et al. Article
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and interactive tool, which also incorporates 
the complexities of service delivery and 
health outcomes. Since many of the health 
insurance stakeholders described return on 
investment as their key driver, they were 
keen to have greater links between the 
intermediate clinical outcomes and cost 
savings. Another suggestion from a Treasury 
stakeholder was that early consultation with 
end users in the development of predictive 
economic models would be beneficial, as 
this would be “getting people to use this kind 
of data [by] helping people to understand 
how it’s done so that it’s not just a sort of 
impenetrable black box”. 
A few stakeholders in Treasury and the 
health departments suggested that lessons 
could be derived from other sectors (e.g. 
transport) in using economic analysis that 
included socioeconomic determinants. 
Indeed, several of the documents referred 
to by the interviewees (health and Treasury 
departments) were evaluation frameworks 
and government strategy documents related 
to policies both within and external to the 
health sector. The evaluation framework 
documents emphasise the importance of 
economic appraisal for efficient allocations 
of resources.20,26 The documents generally 
recommend using cost benefit analysis (CBA) 
and endorse the use of cost-effectiveness 
analyses (CEA) only in some sectors (e.g. 
health) where it may be more difficult to 
monetise the benefits.20,22,23 The strategy 
documents emphasised the importance of 
investing in research that includes economic 
evaluations and implementing cost-effective 
interventions.28,30 In addition, health equity 
and equity in general were highlighted as 
objectives or guiding principles of their 
policies,23,25,27-29 and government evaluation 
guidelines propose that equity impacts 
should be described and quantified when 
possible.20,22 
Prevention agenda for NCD faces 
significant challenges 
Political and ideological considerations
Some stakeholders indicated that promoting 
a prevention agenda is difficult when 
there is a prevailing ideology that can be 
characterised as emphasising personal 
responsibility over government action. A 
few stakeholders suggested that when there 
is a change in government, support for 
prevention programs tends to come under 
closer scrutiny. As a consequence, investment 
in individual prevention programs is tied 
Table 1: Identified barriers to the use of economic analysis in prevention and the prevention agenda and our 
suggested recommendations to overcome them.
Barriers to the use of 
economic analysis 
Recommendations
Lack of relevance of current 
economic analysis to end 
users
For analysts to have a deeper understanding the context of the stakeholders’ perspectives. 
In Australia:
•	 Treasury: managing the governmental budget, thus a whole-of-government approach. Thus, a 
need for strong evidence and economic analysis including effects across different government 
sectors.
•	 Health: a need for a holistic approach towards population health, for there to be an increasing 
appreciation for economic analysis and costs to be included to provide ‘credibility’ for their 
agenda.
•	 Insurance Companies: Financial bottom line for the insurance companies in regards to reducing 
hospitalisation for their members.
Lack of capacity to 
understand health economics 
literature
Building capacity through workshops, in-house health economists, or collaboration, or outsourcing 
through commissioning
Better communication of health economic evidence, to help stakeholders understand its 
significance, such as policy briefs, evaluation frameworks, systematic reviews.
Methodology in prevention is 
a ‘black box’.
Co-production of economic evidence by including decision makers in the development of models 
and making assumptions explicit. 
More development needed in this area to make this economic evidence more accessible to decision 
makers, e.g. Modelling and links between the behavioural risk factors, the clinical risk factors and 
life years saved.
Health economics perceived 
as prioritising costs over 
health outcomes. 
Improving capacity within organisations to understand the fundamentals of health economics (i.e. 
effectiveness, efficiency and equity).
Equity focused economic analysis (e.g. for Indigenous health programs) are needed to provide 
relevant evidence for decision makers.
Barriers to the Prevention 
agenda 
Recommendations
Difficulty maximising upon 
the different approaches of 
prevention as organisational 
perspectives frame the 
preferred prevention 
approaches. 
More collaboration across sectors and health funders to provide prevention programs as a concerted 
effort. 
Priority setting across stakeholders from different sectors will be beneficial.
Established institutional processes for the use of health economics (with standardised methods) in 
prevention.
Develop diverse investment portfolios (i.e. incorporate both high and low-cost interventions with 
variable levels of available evidence) in prevention that consider the potential need for risk to effect 
return and encourages innovation.
Prevailing ideology regarding 
prevention as to whether it 
is personal responsibility or 
government action. 
Understanding and addressing various stakeholders’ views (consumers, health providers, policy 
makers, funders) through consultation. 
Building the evidence base and increasing the public awareness of cost effective prevention 
strategies addressing lifestyle related risk factors as this will affect political will.
Timing of funding cycle is 
short but prevention delivers 
long-term benefits and short-
term benefits are less visible.
The need to use intermediate measures to show progress and modelling to show potential benefits.
This requires the development of a strong infrastructure for the monitoring and evaluation of 
prevention strategies as a prevention platform e.g. IT infrastructure, workforce acceptance of 
performance metrics as part of ongoing monitoring and evaluation, data linkage, use of process 
data.
Use of evidence is varied 
across stakeholders
Evidence generated needs to be pragmatic. There should be more evidence in implementation 
methods, with in-depth contextual understanding.
Increasing preference for co-production of evidence between academic institutions, government 
departments and insurance companies.
More synthesis of the evidence, e.g. through reviews of economic evaluations specific to a particular 
area of prevention such as obesity or tobacco control.
Ways to improve knowledge exchange, e.g. use of databases, policy briefs, knowledge brokers.
The need to incorporate other 
sectors
Including knowledge brokers and the use of economic evidence across sectors
Systems approach to prevention which could be incorporated into research (so that it is not single 
intensity and focused only). This requires a clear picture of the current political influences, health 
system (private, public, out of pocket expenses), other non-health sectoral influences, e.g. market 
forces regarding housing, pharmaceuticals.
effectiveness evidence in obesity, tobacco 
and alcohol in order to understand the 
“current landscape”; to be better equipped 
in economic methods that would suit 
their needs; and to be able to confidently 
commission others to do so. In comparison, 
the insurers did not indicate this request as 
they had in-house personnel with skills in 
economics and modelling. 
Increasing the relevance of health 
economics methodology 
Many respondents described a need for 
economic evidence that serves as a predictive 
204 Australian and New Zealand Journal of Public Health 2018 vol. 42 no. 2
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with an inherent level of uncertainty. In 
response to this, solid evidence plays a role in 
addressing these uncertainties. A participant 
from Treasury described how a strong track 
record of 30 years of evidence was needed 
to enable smoking cessation programs to 
be more acceptable to government decision 
makers, in contrast to how “in overweight and 
obesity, it’s not as clearly understood nor is it 
equally accepted as a place for government 
intervention”.
Prevention delivers long-term benefits; 
short-term benefits are less visible 
There was a general consensus among 
many stakeholders that the delay for health 
promotion and early prevention strategies 
in demonstrating ‘hard’ health outcomes can 
be problematic, due to the constant pressure 
to justify investments in light of competing 
priorities (such as acute care) within short 
funding cycles. The stakeholders emphasised 
that infrastructure in acute care allowed for 
more robust data collection (e.g. number 
of hospitalisations) than the infrastructure 
available to monitor and evaluate preventive 
care. This lack of outcome measures to show 
progress in prevention meant less leverage 
for policy makers when trying to sustain 
funds for prevention as compared to acute 
care. For example, a stakeholder in health 
described getting calls from funders asking 
questions such as: ‘“You’ve now spent this 
huge investment in prevention. How many 
kids did you stop from becoming obese?’ Now 
that’s quite a hard question to answer”. Health 
policy advisors suggested that identifying 
valid “proxies, [such as] people’s behaviour, 
people’s participation, people’s motivation to 
change” may be needed to “predict the future 
[of that] program outcome” and to enable 
these potentially long-term effects to be 
reflected in investment decisions. 
Enabling the commitment to prevention 
requires significant infrastructure
Another key barrier to the prevention agenda 
was the generalisability and scalability of 
effective programs. A Treasury stakeholder 
recognised that “there’s a kind of cost 
trajectory valve, and health costs are going to 
rise into the future” but that the question they 
had was “what we should be investing in … 
you know it’s worked elsewhere, is it actually 
going to work here? Do we have the right 
conditions, capacity and capability?” 
Most participants emphasised that enabling 
evidence-based investment in prevention 
requires advancements in infrastructure, 
including the availability of informative 
(baseline and process) data, processes for 
ongoing data collection and workforce 
capacity building. There was also a stated 
need to leverage other available resources 
(e.g. from primary healthcare, insurance 
companies, hospitals, primary health 
networks). All this would facilitate improved 
monitoring and evaluation, which would 
allow for continued funding and expansion of 
the projects. 
Discussion
Our results highlight the significant political 
and pragmatic challenges faced by decision 
makers in investing in prevention. It is 
within this context that ‘economic’ data 
can sometimes be in a form that does not 
resemble the traditional way that cost-
effectiveness evidence is defined, even 
though it is used routinely by stakeholders. 
The types of evidence used, framed by 
prevailing organisational perspectives, 
include forward estimates of budgetary 
impacts and ‘return on investment’, i.e. range 
of benefits as specific to the organisational 
imperatives of the stakeholders (e.g. decrease 
in hospital admissions for the insurers). 
Furthermore, economic evidence tends to be 
used to support activities such as advocacy, 
financial management and communication 
between stakeholders, which fall outside the 
functions economic evaluations are typically 
designed to inform. Indeed, the finding that 
prevention is seen as part of the branding 
activity by health insurers (regardless of 
prevention’s economic benefit) fits with the 
observation that decision makers often hold 
knowledge to have more symbolic value than 
instrumental value.33
The limited capacity of conventional 
economic evaluation methodologies and 
cost-effectiveness metrics to provide all 
the information decision makers need 
is well recognised in the international 
literature.10-12,34,35 A solution may lie in an 
adoption of an evidence co-production 
approach,36 which means that research is 
characterised as a joint enterprise rather than 
as the end-product of a process in which 
it is ‘delivered’ by researchers to a group of 
decision makers.37 Conversely, more work can 
be done to encourage decision makers to 
look beyond their organisational perspectives 
and to take on board evidence of societal 
and sector-wide impacts. This may include 
promoting recent initiatives in the health 
economics literature such as the use of cost 
consequences analyses of ‘social impact 
inventories’, which represent evaluation 
techniques that take multi-dimensional social 
outcomes into account.38,39 
Another key implication is that economic 
evaluation tools could potentially address 
some of the barriers faced by prevention 
programs (e.g. short-term benefits are less 
visible). Thus, an area for further development 
is for health economic researchers to re-orient 
analyses in prevention so that evidence can 
be used to guide future action, rather than 
as a means of evaluating past decisions. This 
requires greater use of modelling techniques 
based on epidemiological evidence to 
provide decision makers with stronger 
predictive capabilities. In addition, the use 
of priority setting tools such as program 
budgeting and marginal analysis that involve 
the decision maker in the process40,41 and 
studies41,42 that synthesise existing evidence 
and incorporate a broader concept of benefit 
would be useful in prospectively informing 
investment decisions.
Given the dynamic nature of the political 
and ideological context around prevention, 
stronger national leadership and establishing 
processes for the use of health economics 
within organisations may be needed.43,44 
Advances in the use of economic evaluations 
in policy in Australia have mainly been in 
the field of health technology assessments 
for drugs and devices. We had expected 
this to filter through to prevention, but 
our evidence suggests that this has not 
happened to any major extent. A reason 
inferred from the findings was that 
implementation of prevention programs (e.g. 
taxation of soft drinks) faces political and 
ideological challenges and that consumer 
acceptability is key in this process. While a 
universal PBAC-type system for assessment 
of new prevention ‘technologies’ may be 
challenging given the diversity of funders 
and organisational imperatives that drive 
decision making in the prevention sphere, 
the evolution of the partnership between 
UK Department of Health and the National 
Institute for Health and Care Excellence (NICE) 
to provide evidence-based recommendations 
for public health practitioners and policy 
makers indicates that such challenges can 
be overcome.6,45,46 As indicated in this study, 
much of the evidence sought by those 
charged with investing in prevention falls 
outside the purview of what is conventionally 
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considered health economic evidence and is 
specific to organisation. Part of the solution 
is in encouraging the application of existing 
methods of economic analysis that are 
sympathetic to what it is that prevention 
achieves, and the other part is to create the 
incentives for decision makers to factor into 
their investment decisions outcomes that 
are broader than their narrow organisational 
perspectives.1,7
A limitation of the study may be the small 
number of participants, although it should 
be recognised that our focus was on senior-
level decision makers, and that we did 
achieve thematic saturation. Sampling from 
the different organisations also provided 
triangulation from different perspectives 
given the relevance of the public and private 
sector in the prevention agenda. It is possible 
that a level of social desirability may have 
biased the findings, given that the interviews 
were led by a health economist. However, we 
found respondents to be candid and openly 
critical of economics and often highlighted 
organisational shortcomings in addressing 
issues raised. 
Conclusion
To ensure the better use of evidence in 
investment in prevention in Australia, 
researchers need to be attuned to the varied 
organisational imperatives faced by the 
various organisations who are players in 
this space. Evidence needs to be fit for such 
purposes but, at the same time, more can be 
done to encourage potential funders to take 
into account cost-effectiveness evidence that 
highlights cross sector and societal impacts. 
This will require significant infrastructure 
development, monitoring and evaluation, 
stronger national leadership and a greater 
emphasis on evidence co-production. 
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